Stratec SE (SBS.F)
- Previous Close
39.90 - Open
41.25 - Bid 41.20 x 20000
- Ask 41.90 x 20000
- Day's Range
41.25 - 41.25 - 52 Week Range
36.55 - 68.50 - Volume
50 - Avg. Volume
28 - Market Cap (intraday)
520.282M - Beta (5Y Monthly) 0.13
- PE Ratio (TTM)
38.55 - EPS (TTM)
1.07 - Earnings Date Apr 26, 2024
- Forward Dividend & Yield 0.55 (1.38%)
- Ex-Dividend Date May 20, 2024
- 1y Target Est
46.80
Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers; and offers complex consumables for diagnostics and medical applications. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
www.stratec.comRecent News: SBS.F
Performance Overview: SBS.F
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SBS.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SBS.F
Valuation Measures
Market Cap
503.26M
Enterprise Value
610.41M
Trailing P/E
37.29
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.85
Price/Book (mrq)
2.08
Enterprise Value/Revenue
2.33
Enterprise Value/EBITDA
15.29
Financial Highlights
Profitability and Income Statement
Profit Margin
4.99%
Return on Assets (ttm)
3.72%
Return on Equity (ttm)
5.70%
Revenue (ttm)
261.91M
Net Income Avi to Common (ttm)
13.07M
Diluted EPS (ttm)
1.07
Balance Sheet and Cash Flow
Total Cash (mrq)
33.53M
Total Debt/Equity (mrq)
60.59%
Levered Free Cash Flow (ttm)
-14.63M
Research Analysis: SBS.F
Company Insights: SBS.F
SBS.F does not have Company Insights